ABSTRACT
A causal link between viral infections and autoimmunity has been studied for a long time and the role of some viruses in the induction or exacerbation of systemic lupus erythematosus (SLE) in genetically predisposed patients has been proved. The strength of the association between different viral agents and SLE is variable. Epstein-Barr virus (EBV), parvovirus B19 (B19V), and human endogenous retroviruses (HERVs) are involved in SLE pathogenesis, whereas other viruses such as Cytomegalovirus (CMV) probably play a less prominent role. However, the mechanisms of viral-host interactions and the impact of viruses on disease course have yet to be elucidated. In addition to classical mechanisms of viral-triggered autoimmunity, such as molecular mimicry and epitope spreading, there has been a growing appreciation of the role of direct activation of innate response by viral nucleic acids and epigenetic modulation of interferon-related immune response. The latter is especially important for HERVs, which may represent the molecular link between environmental triggers and critical immune genes. Virus-specific proteins modulating interaction with the host immune system have been characterized especially for Epstein-Barr virus and explain immune evasion, persistent infection and self-reactive B-cell "immortalization". Knowledge has also been expanding on key viral proteins of B19-V and CMV and their possible association with specific phenotypes such as antiphospholipid syndrome. This progress may pave the way to new therapeutic perspectives, including the use of known or new antiviral drugs, postviral immune response modulation and innate immunity inhibition. We herein describe the state-of-the-art knowledge on the role of viral infections in SLE, with a focus on their mechanisms of action and potential therapeutic targets.
Subject(s)
Cytomegalovirus/immunology , Endogenous Retroviruses/immunology , Herpesvirus 4, Human/immunology , Immunity, Innate/immunology , Lupus Erythematosus, Systemic/immunology , Parvovirus B19, Human/immunology , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/virology , Autoimmunity/immunology , Cytomegalovirus Infections/pathology , Endogenous Retroviruses/physiology , Epstein-Barr Virus Infections/pathology , Herpesvirus 4, Human/physiology , Host-Pathogen Interactions/physiology , Humans , Lupus Erythematosus, Systemic/virology , Parvoviridae Infections/pathology , Parvovirus B19, Human/physiologyABSTRACT
Human parvovirus B19 (B19V) infection has symptoms similar to those of antiphospholipid syndrome (APS). Antibodies against B19VVP1 unique region (VP1u) exhibit activity similar to that of antiphospholipid antibodies (aPLs) by inducing vascular endothelial cell adhesion factors and APSlike syndrome. Previous studies have identified an effect of aPLs on angiogenesis. However, little is understood regarding the effect of antiB19VVP1u antibodies on angiogenesis. The present study investigated the effects of antiB19VVP1u antibodies on the expression of adhesion molecules and angiogenic signaling using an aPLinduced human umbilical vein endothelial cell (HUVEC) model, and trypan blue staining and western blotting. The effect of B19VVP1u antibodies on vascular endothelial growth factor (VEGF) expression in A549 cells, another wellknown model used to study angiogenesis, was also examined. Significantly higher intracellular adhesion molecule 1 expression was observed following treatments with 10% fetal calf serum (FCS), aPL immunoglobulin G (IgG), B19VVP1u IgG or B19VNS1 IgG, compared with in the normal human (NH) IgGtreated cells. Conversely, significantly higher vascular cellular adhesion molecule 1 was only detected in HUVECs treated with B19VVP1u IgG. Significantly increased integrin ß1 was detected in HUVECs treated with aPL IgG or B19VVP1u IgG, whereas no difference in integrin ß1 was observed in those treated with 10% FCS, NH IgG or B19VNS1 IgG. No difference in AKTmTORS6 ribosomal protein (S6RP) signaling was observed in HUVECs treated with B19VP1u IgG or B19VNS1 IgG, compared with NH IgGtreated cells. Significantly higher human inducible factor1α was detected in HUVECs treated with 10% FCS, aPL IgG, B19VVP1u IgG or B19VNS1 IgG, compared with in NH IgGtreated cells. However, there was no difference in the level of VEGF observed among HUVECs treated with NH IgG, B19VVP1u IgG or B19VNS1 IgG. Notably, no difference in VEGF level was observed in A549 cells treated with NH IgG, aPL IgG, B19VVP1u IgG or B19VNS1 IgG. These findings suggest that antiB19VVP1u antibodies may serve a role in activating adhesion molecules, but not in AKTmTORS6RP signaling.
Subject(s)
Antibodies, Viral/pharmacology , Antiphospholipid Syndrome , Erythema Infectiosum , Immunoglobulin G/pharmacology , Neovascularization, Physiologic/drug effects , Parvovirus B19, Human/metabolism , Signal Transduction/drug effects , A549 Cells , Antibodies, Antiphospholipid/pharmacology , Antiphospholipid Syndrome/metabolism , Antiphospholipid Syndrome/pathology , Antiphospholipid Syndrome/virology , Erythema Infectiosum/metabolism , Erythema Infectiosum/pathology , Human Umbilical Vein Endothelial Cells , HumansABSTRACT
PURPOSE OF REVIEW: The antiphospholipid syndrome (APS) is characterized by the development of thrombotic events and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). An infectious etiology for this syndrome has been postulated. The present review is aimed to summarize recent evidence about the role of infections and vaccines in the pathogenesis of the APS (including its catastrophic variant). RECENT FINDINGS: There is an increased risk of developing aPL in various infections, particularly in viral infections. The most frequent infection related to aPL has been hepatitis C virus. These antibodies may be associated with thromboembolic events, including catastrophic APS. There is a link between vaccinations, such as the tetanus toxoid and aPL, due to molecular mimicry between the two molecules. Accumulated evidence supports that the presence of aPL is associated with a variety of infections, including viruses, bacteria, fungi, and parasites, and the main mechanism to explain this correlation is molecular mimicry. Moreover, a link between vaccinations, such as the tetanus toxoid, and APS has also been described.
Subject(s)
Antiphospholipid Syndrome/virology , Bacterial Infections/complications , Virus Diseases/complications , Hepatitis C/complications , Humans , Tetanus/complicationsABSTRACT
There is growing evidence that the commensal bacteria in the gastrointestinal tract (the gut microbiota) influence the development of autoimmunity in rodent models. Since humans have co-evolved with commensals for millennia, it is likely that people, who are genetically predisposed to autoimmunity, harbor gut microbial communities that similarly influence the onset and/or severity of disease. Beyond the current efforts to identify such disease-promoting or -preventing commensals ("pathobionts" or "symbionts"), it will be important to determine what factors modulate them. Dietary changes are known to affect both the composition and function of the gut microbial communities, which in turn can alter the innate and adaptive immune system. In this review, we focus on the relationships between diet, microbiota, and autoimmune diseases. We hypothesize that the beneficial and life-prolonging effects of caloric restriction on a variety of autoimmune models including lupus might partly be mediated by its effects on the gut microbiome and associated virome, the collection of all viruses in the gut. We give recent examples of the immunomodulatory potential of select gut commensals and their products or diet-derived metabolites in murine models of arthritis, multiple sclerosis, and type 1 diabetes. Lastly, we summarize the published phenotypes of germ-free mouse models of lupus and speculate on any role of the diet-sensitive microbiome and virome in systemic lupus and the related antiphospholipid syndrome.
Subject(s)
Antiphospholipid Syndrome/etiology , Autoimmunity , Diet/adverse effects , Lupus Erythematosus, Systemic/etiology , Microbiota , Animals , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/microbiology , Antiphospholipid Syndrome/therapy , Antiphospholipid Syndrome/virology , Caloric Restriction , Disease Models, Animal , Gastrointestinal Tract/microbiology , Gastrointestinal Tract/virology , Host-Pathogen Interactions , Humans , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/microbiology , Lupus Erythematosus, Systemic/therapy , Lupus Erythematosus, Systemic/virology , Mice , Risk Assessment , Risk FactorsSubject(s)
Brain Ischemia/etiology , Cerebral Arterial Diseases/virology , Herpes Zoster/complications , Herpesvirus 3, Human/pathogenicity , Peripheral Vascular Diseases/etiology , Thrombosis/etiology , Adult , Antiphospholipid Syndrome/virology , Brain Ischemia/virology , Cerebral Arterial Diseases/complications , Cerebral Arteries/virology , Hemianopsia/etiology , Hemiplegia/etiology , Humans , Male , Perceptual Disorders/etiology , Peripheral Vascular Diseases/virology , Protein S Deficiency/virology , Retinal Artery Occlusion/etiology , Retinal Artery Occlusion/virology , Thrombophilia/virology , Thrombosis/virologyABSTRACT
The case of a patient with basal ganglia infarction associated with primary human herpesvirus-6 infection is reported. Anticardiolipin antibody immunoglobulin G was elevated after human herpesvirus-6 infection and then decreased gradually. The transient elevation in the antiphospholipid antibody level suggests that the human herpesvirus-6 infection can induce antiphospholipid syndrome, thus resulting in a cerebral infarction.
Subject(s)
Antiphospholipid Syndrome/etiology , Antiphospholipid Syndrome/virology , Herpesviridae Infections/complications , Herpesvirus 6, Human/pathogenicity , Antibodies/blood , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/diagnosis , Cardiolipins/immunology , Cerebral Infarction/etiology , Cerebral Infarction/virology , Child, Preschool , Herpesviridae Infections/blood , Humans , Magnetic Resonance Angiography/methods , Magnetic Resonance Imaging/methods , Male , Retrospective StudiesABSTRACT
BACKGROUND: Previous studies have postulated a connection between human parvovirus B19 (B19) infection and anti-phospholipid antibodies (APhL). B19 infection and anti-phospholipid syndrome (APS) exhibit congruent symptoms. Recently, phospholipase A2 (PLA2)-like activity has been linked to the VP1 unique region (VP1u) of B19. However, the precise role of B19-VP1u in pathogenesis of autoimmunity is still obscure. METHODS: To elucidate the roles of VP1u in B19 infection and autoimmunity, the reactivity of B19-VP1u proteins with various autoantibodies were evaluated by ELISA and immunoblotting. Rabbits were immunized with purified recombinant B19-VP1u protein to generate anti-sera. Absorption experiments were conducted to determine the binding specificity of rabbit anti-sera against B19-VP1u, cardiolipin (CL) and beta-2-glycoprotein I (beta2GPI). Moreover, the effects of passive transfer of polyclonal rabbit anti-B19-VP1u IgG antibodies on platelets, activated partial thromboplastin time (aPTT), and autoantibodies were assessed. RESULTS: Autoantibodies against CL, beta2GPI, and phospholipid (PhL) in sera from patients with B19 infection, were cross-reactive with B19-VP1u. Consistently, sera from rabbits immunized with recombinant B19-VP1u protein displayed raised detectable immunoglobulins against B19-VP1u, CL, beta2GPI and PhL. Additionally, the mice immunized with anti-B19-VP1u IgG developed thrombocytopenia, prolongation of aPTT, and autoantibody against beta2GPI and PhL. CONCLUSIONS: These experimental results suggested the association between B19-VP1u and production of anti-beta2GPI antibodies, APhL, and APS-like autoimmunity. Altogether, it may provide a clue in understanding the role of B19-VP1u in inducing autoantibodies and B19-associated APS manifestations.
Subject(s)
Antibodies, Antiphospholipid/immunology , Antibody Specificity/immunology , Antiphospholipid Syndrome/immunology , Autoimmunity/immunology , Capsid Proteins/immunology , Parvovirus B19, Human/immunology , Animals , Antibodies, Antiphospholipid/metabolism , Antibody Formation , Antiphospholipid Syndrome/virology , Autoantibodies , Disease Models, Animal , Female , Mice , Mice, Inbred BALB C , RabbitsSubject(s)
Autoimmune Diseases , Hepatitis C, Chronic , Antiphospholipid Syndrome/physiopathology , Antiphospholipid Syndrome/virology , Arthritis, Rheumatoid/physiopathology , Arthritis, Rheumatoid/virology , Autoimmune Diseases/physiopathology , Autoimmune Diseases/virology , Hepacivirus/genetics , Hepacivirus/pathogenicity , Hepatitis C, Chronic/immunology , Hepatitis C, Chronic/physiopathology , Humans , Lupus Erythematosus, Systemic/physiopathology , Lupus Erythematosus, Systemic/virology , Mexico , Sjogren's Syndrome/physiopathology , Sjogren's Syndrome/virologyABSTRACT
High prevalence of anticardiolipin antibodies and antiphospholipid antibodies has been reported in human immunodeficiency virus (HIV)-infected patients. A full blown clinical picture of antiphospholipid syndrome (APLS) is rare and rarely reported, even in HIV-infected adults and has never been reported in HIV-infected children. We report an HIV-infected child with left sided choreoathetosis associated with APLS.
Subject(s)
Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/virology , HIV Infections/complications , HIV Infections/immunology , Antibodies, Anticardiolipin/blood , Antibodies, Antiphospholipid/blood , Child , HIV Infections/virology , HIV-1 , Humans , MaleABSTRACT
An unusual variant of the antiphospholipid syndrome (APS) termed the Catastrophic Antiphospholipid Syndrome (CAPS) in 1992 by Asherson is described. The condition may arise "de-novo" in a patient previously not suspected of having an APS or during the course of a "Primary" APS or Secondary APS (most commonly SLE). The patient may already be on therapy. "Trigger" factors (infections most commonly) have been identified in 45% of patients but in the majority, they remain unidentified. Clinically, the patients present with small vessel occlusions involving organs (e.g. bowel, brain, heart, kidney) but large vessels occlusions do occur. Unusual organs are involved and the clinical features depend on which organs are affected. Because of tissue necrosis, the Systemic Inflammatory Response ensues ("SIRS") and many patients develop ARDS. Despite seemingly adequate therapy (parenteral heparin, steroids, antibiotics), the mortality remains high (approximately 50%).
Subject(s)
Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/microbiology , Antiphospholipid Syndrome/physiopathology , Antiphospholipid Syndrome/therapy , Antiphospholipid Syndrome/virology , Communicable Diseases/immunology , HumansABSTRACT
An 11-year-old girl developed proximal deep venous thrombosis and bilateral pulmonary embolism associated with antiphospholipid syndrome following chickenpox. She responded to prolonged anticoagulation therapy.
Subject(s)
Antiphospholipid Syndrome/virology , Chickenpox/complications , Pulmonary Embolism/virology , Venous Thrombosis/virology , Child , Female , Humans , Pulmonary Embolism/diagnosis , Venous Thrombosis/diagnosisABSTRACT
There is a high incidence of antiphospholipid antibodies, detected by assays for anticardiolipin or lupus-like anticoagulant, in HIV disease. However, a link to the antiphospholipid syndrome, with clinical thrombosis, is tenuous. We report a case of a 25-year-old man with undetermined risk factors for HIV presenting with possible antiphospholipid syndrome manifesting as necrotic skin lesions as the initial clinical presentation for HIV. We also review the literature exploring the association between HIV and antiphospholipid syndrome.
Subject(s)
Antibodies, Antiphospholipid/biosynthesis , Antiphospholipid Syndrome/virology , HIV Infections/complications , HIV Infections/immunology , Adult , Antibodies, Anticardiolipin/biosynthesis , Humans , Male , Necrosis , Skin Diseases/immunology , Skin Diseases/pathology , Skin Diseases/virology , Thrombosis/immunology , Thrombosis/pathology , Thrombosis/virologyABSTRACT
Morphology of gastric mucosa is characterized in the presence of Helicobacter pylori (HP) and Herpes viruses (HSV-1 and CMV). A total of 85 patients were examined (20 patients with primary APS and 65 with SLE). Chronic active gastritis was revealed in 85% patients with APS and 96% with SLE. 60% patients with APS and 45% with SLE had mucosal erosions. HP was detected in 70-87% of cases. Mixed infection of the gastric mucosa was observed in all the groups which was significantly associated with increased fibroblast and plasma cell number in the tunica propria. Tissue eosinophilia of the antral part of the stomach was observed in 39% of SLE patients. Glucocorticoid therapy was not associated with erosions and was combined with vascular thrombosis of gastric mucosa.
Subject(s)
Antiphospholipid Syndrome/pathology , Cytomegalovirus Infections/pathology , Gastric Mucosa/pathology , Helicobacter Infections/pathology , Herpes Simplex/pathology , Lupus Erythematosus, Systemic/pathology , Adult , Antiphospholipid Syndrome/microbiology , Antiphospholipid Syndrome/virology , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/virology , Female , Gastric Mucosa/microbiology , Gastric Mucosa/virology , Helicobacter Infections/microbiology , Helicobacter pylori/isolation & purification , Herpes Simplex/virology , Herpesvirus 1, Human/isolation & purification , Humans , Lupus Erythematosus, Systemic/microbiology , Lupus Erythematosus, Systemic/virology , Male , Polymerase Chain ReactionABSTRACT
BACKGROUND: Although controversial, some authorities have implicated hepatitis C virus (HCV) as a cause of anti-phospholipid syndrome (APLS). Anti-cardiolipin antibodies (anti-CLAbs) in APLS are cofactor-dependent ('pathogenic' antibodies). We conducted a study in order to determine the prevalence of anti-CLAbs in HCV patients, and furthermore to address whether these autoantibodies are cofactor-dependent or not and whether they are associated with features of APLS. Patients with hepatitis B virus (HBV) were also evaluated in order to assess whether there are differences in the prevalence and the clinical significance of anti-CLAbs between these two major types of chronic viral hepatitis. MATERIALS AND METHODS: One hundred and seventy-four consecutive HCV patients, 50 HBV patients and 267 healthy were investigated for the presence of anti-CLAbs and antibodies against beta2-glycoprotein I (beta2-GPI), which is the most important cofactor of the 'pathogenic' anti-CLAbs in APLS. IgG anti-CLAbs were determined by an in-house quantitative ELISA and anti-beta2-GPIAbs using a commercial ELISA kit. RESULTS: 21.3% of the HCV and 14% of the HBV patients tested positive for IgG anti-CLAbs (P < 0.0001 compared with healthy controls). Neither age, sex, certain epidemiologic and laboratory parameters nor the clinical status and the histologic findings were associated with anti-CLAbs detection in both diseases. 2.3% of the HCV (P < 0.05 compared with healthy controls) and 2% of the HBV patients tested positive for anti-beta2-GPIAbs. Presence of anti-CLAbs was not associated with features of APLS. CONCLUSIONS: A significant proportion of the HCV and HBV patients had detectable IgG anti-CLAbs. However, the anti-CLAbs titres were relatively low, and in most cases seem to be cofactor-independent ('nonpathogenic'). The latter is further supported by the lack of their association with clinical features of APLS. Furthermore, anti-CLAbs appear to be detected irrespective of the demographic, laboratory, clinical and histologic status in both HCV and HBV. However, prospective studies of longer duration may be required in order to address whether anti-CLAbs in patients with chronic viral hepatitis are or are not of clinical importance.